Barclays
ABCL icon

Barclays’s AbCellera Biologics ABCL Stock Holding History

Barclays’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.04M Sell
71,220
-13,414
-16% -$127K ﹤0.01% 3026
2026
Q2 		$664K Buy
84,634
+35,160
+71% +$172K ﹤0.01% 3048
2026
Q1 		$173K Buy
49,474
+15,927
+47% +$57.3K ﹤0.01% 3775
2025
Q4 		$115K Buy
33,547
+2,649
+9% +$11.8K ﹤0.01% 4541
2025
Q3 		$155K Sell
30,898
-12,130
-28% -$53.5K ﹤0.01% 4440
2025
Q2 		$148K Buy
43,028
+1,133
+3% +$2.82K ﹤0.01% 4463
2025
Q1 		$93.4K Buy
41,895
+3,544
+9% +$10.2K ﹤0.01% 4432
2024
Q4 		$112K Buy
38,351
+16,058
+72% +$44.7K ﹤0.01% 4568
2024
Q3 		$58K Buy
22,293
+1,465
+7% +$4.06K ﹤0.01% 4714
2024
Q2 		$61.7K Sell
20,828
-151,530
-88% -$573K ﹤0.01% 4123
2024
Q1 		$781K Buy
172,358
+51,701
+43% +$264K ﹤0.01% 3307
2023
Q4 		$689K Buy
120,657
+99,671
+475% +$462K ﹤0.01% 3687
2023
Q3 		$96.5K Sell
20,986
-504,978
-96% -$3.07M ﹤0.01% 3615
2023
Q2 		$3.4M Buy
525,964
+5,443
+1% +$37.1K ﹤0.01% 1585
2023
Q1 		$3.92M Buy
520,521
+203,493
+64% +$1.85M ﹤0.01% 1714
2022
Q4 		$3.21M Buy
317,028
+80,630
+34% +$931K ﹤0.01% 1931
2022
Q3 		$2.34M Sell
236,398
-4,830
-2% -$53K ﹤0.01% 1640
2022
Q2 		$2.57M Sell
241,228
-6,842
-3% -$57.9K ﹤0.01% 1676
2022
Q1 		$2.42M Buy
+248,070
New +$2.35M ﹤0.01% 1726

Other funds holding ABCL

TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Guardian Partners
Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Citizens Financial Group
Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Barclays's ABCL Position: Q3 2026 in Review

Barclays reduced its AbCellera Biologics (ABCL) stake by 16% in Q3 2026, selling an estimated $127K and leaving 71,220 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3026.

Barclays first reported a position in ABCL in Q1 2022 and has held it in 19 quarters since. The position peaked at $3.92M in Q1 2023. 64 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Barclays held 71,220 shares of AbCellera Biologics worth $1.04M as of Q3 2026.
  • Barclays sold 13,414 AbCellera Biologics shares in Q3 2026, an estimated $127K.
  • AbCellera Biologics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3026 holding.
  • Barclays first reported a position in AbCellera Biologics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's AbCellera Biologics position peaked at $3.92M in Q1 2023.
  • 64 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.